Overview

Smoke-Free Living Study

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to provide you with an effective treatment for reducing the physical and emotional stress that can occur during the early phase of being without cigarettes. It is our hope that this treatment will help you to stay smoke-free. You will receive counseling and a supply of Champix, a medication to help suppress the symptoms of nicotine withdrawal. Purpose: To assess the effect of extended Integrated Voice Response (IVR) on smoking cessation after varenicline (Champix) and IVR treatment Hypothesis: There will be significant increase in participants who do not smoke at 1 year if extended IVR is used after 12 weeks of varenicline (Champix) and IVR treatment.
Phase:
Phase 1
Details
Lead Sponsor:
University of British Columbia
Collaborator:
Pfizer
Treatments:
Varenicline